Koninklijke Philips (NYSE:PHG) Shares Gap Up to $20.06

Koninklijke Philips (NYSE:PHG) shares gapped up prior to trading on Monday . The stock had previously closed at $20.06, but opened at $20.66. Koninklijke Philips shares last traded at $20.69, with a volume of 104,334 shares traded.

Analysts Set New Price Targets

A number of brokerages have recently issued reports on PHG. BNP Paribas cut Koninklijke Philips from an “outperform” rating to an “underperform” rating in a report on Wednesday, February 7th. StockNews.com raised Koninklijke Philips from a “buy” rating to a “strong-buy” rating in a report on Thursday, February 8th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating, one has assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $19.00.

Koninklijke Philips Price Performance

The company has a 50 day moving average price of $20.40 and a 200 day moving average price of $20.86. The company has a market capitalization of $18.88 billion, a price-to-earnings ratio of -35.67, a PEG ratio of 1.04 and a beta of 0.88. The company has a current ratio of 1.20, a quick ratio of 0.78 and a debt-to-equity ratio of 0.58.

Koninklijke Philips (NYSE:PHG) last posted its quarterly earnings results on Monday, January 29th. The technology company reported $0.44 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.41 by $0.03. Koninklijke Philips had a positive return on equity of 14.17% and a negative net margin of 2.53%. The business had revenue of $5.45 billion for the quarter, compared to analyst estimates of $5.47 billion. As a group, equities research analysts forecast that Koninklijke Philips will post 1.52 earnings per share for the current year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in PHG. Citigroup Inc. raised its stake in shares of Koninklijke Philips by 1.3% in the 1st quarter. Citigroup Inc. now owns 36,882 shares of the technology company’s stock valued at $1,126,000 after purchasing an additional 483 shares during the period. Advisory Services Network LLC increased its position in shares of Koninklijke Philips by 28.7% in the first quarter. Advisory Services Network LLC now owns 2,226 shares of the technology company’s stock valued at $41,000 after acquiring an additional 496 shares during the last quarter. Capital Analysts LLC increased its position in shares of Koninklijke Philips by 6.3% in the fourth quarter. Capital Analysts LLC now owns 8,820 shares of the technology company’s stock valued at $206,000 after acquiring an additional 521 shares during the last quarter. Vident Advisory LLC increased its position in shares of Koninklijke Philips by 3.5% in the fourth quarter. Vident Advisory LLC now owns 17,290 shares of the technology company’s stock valued at $403,000 after acquiring an additional 581 shares during the last quarter. Finally, Dorsey & Whitney Trust CO LLC increased its position in shares of Koninklijke Philips by 5.7% in the fourth quarter. Dorsey & Whitney Trust CO LLC now owns 11,374 shares of the technology company’s stock valued at $265,000 after acquiring an additional 615 shares during the last quarter. 13.67% of the stock is currently owned by institutional investors.

Koninklijke Philips Company Profile

Koninklijke Philips N.V. operates as a health technology company in North America, the Greater China, and internationally. The company operates through Diagnosis & Treatment Businesses, Connected Care Businesses, and Personal Health Businesses segments. It also provides diagnostic imaging solutions, includes magnetic resonance imaging, X-ray systems, and computed tomography (CT) systems and software comprising detector-based spectral CT solutions, as well as molecular and hybrid imaging solutions for nuclear medicine; echography solutions focused on diagnosis, treatment planning and guidance for cardiology, general imaging, obstetrics/gynecology, and point-of-care applications; integrated interventional systems, and interventional diagnostic and therapeutic devices to treat coronary artery and peripheral vascular disease.